Efficacy of Metoclopramide in Poor Ovarian Response IVF Patients

Not Applicable

Recruiting

• Conditions: Poor Responders in IVF
• Interventions: Drug: Metoclopramide; Drug: Placebo Oral Tablet

• Registration Number: NCT03560583
• Lead Sponsor: Barzilai Medical Center

Brief Summary

Poor ovarian response population of ART are considered the biggest challenge for providers. Hitherto, no one protocol has been proven to be effect in this subgroup of IVF patients.

Metoclopramide belongs to the antiemetic group, used for motion sickness and during early gestation for hyperemesis gravidarum.

The mechanism of action is antagonisim to dopamine receptors. We hypothesize than by blocking dopamine receptors and decreasing the dopaminergic tone there is a possibility to increase the sensitivity of ovarian response to gonadotropins during controlled ovarian stimulation and result in increased oocyte retrival.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-06-07
• Study First Submitted QC: 2018-06-07
• Study First Posted: 2018-06-18
• Study Start: 2021-05-05
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-06
• Last Update Posted: 2025-02-10
• Primary Completion: 2027-12
• Study Completion: 2028-07

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

• Poor response according to "Bologna criteria"

Exclusion Criteria

• Allergy to metoclopramide
• Prolactinemia
• Women treated with dopamine agonists

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Metoclopramide 10 mg BID	Metoclopramide	-
Placebo 10 mg BID	Placebo Oral Tablet	-

Primary Outcome Measures

Name	Time	Method
Number of oocytes	Approximately 5 weeks from first dose of study drug	Number of oocytes

Trial Locations

Locations (1)

Barzilai University Medical Center; 🇮🇱 Ashkelon, Ashkelon District, Israel